ERBB2 and breast carcinoma: Besides, one comparative analysis of signal pathway mutations derived from second-generation sequencing (NGS) of gene panels among breast cancer patients and demonstrated that there might be more gene mutations in the PI3K-Akt signaling pathway of HER2-low tumors than HER2-positive and HER2-negative tumors [7].